Craft

Pluri Biotech

Stock Price

$4.6

2024-10-29

Market Capitalization

$25.2 M

2024-10-29

Revenue

$1.3 M

FY, 2025

Pluri Biotech Summary

Company Summary

Overview
Pluri Biotech (פלורי ביוטק בע"מ, formerly Pluristem Therapeutics) is a clinical-stage biotherapy company developing cell therapies. It uses placental cells and a three-dimensional technology platform to treat conditions such as inflammation, ischemia, muscle injuries, hematological disorders, and exposure to radiation.
Type
Public
Status
Active
Founded
2003
HQ
Haifa, IL | view all locations
Website
https://pluri-biotech.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Zami Aberman

    Zami Aberman, Executive Chairman

    • Yaky Yanay

      Yaky Yanay, CEO & President, Board Member

      • Racheli Ofir

        Racheli Ofir, VP Research & Intellectual Property

        • Efrat Livne-Hadass

          Efrat Livne-Hadass, VP Human Resources

          LocationsView all

          2 locations detected

          • Haifa, Haifa District HQ

            Israel

            Andrei Sakharov 9 St Building 25, 8th floor

          • Potsdam, BB

            Germany

            Brentanoweg 9

          Pluri Biotech Financials

          Summary Financials

          Revenue (Q3, 2026)
          $167.0K
          Gross profit (Q3, 2026)
          $56.0K
          Net income (Q3, 2026)
          ($6.2M)
          Cash (Q3, 2026)
          $3.4M
          EBIT (Q3, 2026)
          ($6.5M)
          Enterprise value
          $49.1M

          Footer menu